Breaking Down Aurisco Pharmaceutical Co.,Ltd. Financial Health: Key Insights for Investors

Aurisco Pharmaceutical Co., Ltd., founded in 1998 and headquartered in Shanghai, blends a steadfast mission to 'create a better world' through the highest-quality pharmaceuticals with a clear vision to be a global leader, supported by a network of four manufacturing facilities, five R&D centers and sales branches across the United States, Europe, India and South America; with more than 20 years in complex API and finished dosage development, long-term partnerships with leading global pharma firms, and bold sustainability targets - carbon neutrality by 2027 and zero emissions by 2030 - Aurisco's commitment to honesty, integrity and the 'One team, One dream' culture drives its strategic investments in R&D and global expansion, making the company's mission, vision and core values a compelling blueprint for its next chapter.

Aurisco Pharmaceutical Co.,Ltd. (605116.SS) - Intro

• Founding year: 1998; HQ: Shanghai, China.
• Manufacturing footprint: 4 GMP-compliant facilities (APIs, sterile injectables, oral solids, specialty intermediates).
• R&D network: 5 research centers focusing on process chemistry, formulation development, analytical science, biologics-enabling technologies and regulatory affairs.
• Global commercial presence: sales branches in the United States, Europe, India and South America; export-led revenue mix.
• Strategic alliances: long-term partnerships with multiple renowned global pharmaceutical enterprises for co-development, supply and licensing agreements.

• Deliver high-quality, complex APIs and finished dosage forms that improve patient outcomes worldwide.
• Advance pharmaceutical science through relentless process innovation and scalable manufacturing.
• Operate responsibly with a focus on safety, compliance and environmental stewardship.

• Be a globally trusted partner for innovative medicines-providing reliable supply, technical excellence and rapid access to life-changing therapies.
• Transform Aurisco into an internationally recognized leader in sustainable pharmaceutical manufacturing by 2030.

• Scale high-margin complex APIs and sterile injectable capacity to meet rising global demand.
• Accelerate R&D translation: shorten IND-to-commercial timelines via platform process development.
• Execute sustainability targets with measurable KPIs: GHG reduction, energy intensity and waste diversion.

• Energy: upgrade to high-efficiency boilers, onsite solar deployment and electrification of heating processes.
• Emissions: process optimization and methane/NOx control systems to meet carbon-neutral target by 2027.
• Waste & water: closed-loop solvent recovery and >70% water reuse target in production by 2028.

Aurisco Pharmaceutical Co.,Ltd. (605116.SS) - Overview

• Commitment to quality: Aurisco emphasizes manufacturing and quality-control systems designed to meet and exceed international regulatory standards, ensuring product safety and efficacy.
• Societal impact: The phrase "creating a better world" signals commitments beyond commercial outcomes - improving public health, expanding access to medicines, and supporting community health initiatives.
• Consistency over time: The mission has remained stable across corporate communications and investor disclosures, reflecting long-term strategic continuity.
• R&D alignment: Investment priorities and pipeline focus align with the mission to deliver innovative, effective healthcare solutions that address unmet medical needs.

Aurisco Pharmaceutical Co.,Ltd. (605116.SS) - Mission Statement

• Ambition: Achieve prominence in the global pharmaceutical industry through product innovation and strategic partnerships.
• Leadership focus: Set industry standards in quality, compliance, and therapeutic impact rather than follow peers.
• Consistency: Maintain a stable, long-term vision that guides capital allocation, talent development, and market entry decisions.
• Strategy drivers: Geographic expansion, M&A for complementary assets, and deepening R&D capabilities.

• R&D prioritization: A sustained allocation of ~6-8% of annual revenue to R&D supports clinical progression and new product registration in key markets.
• Pipeline emphasis: Focus on specialty generics, oncology biologics, and niche innovative small molecules to balance near-term revenue and long-term growth.
• Global footprint: Targeted expansion into Southeast Asia, Europe, and selected emerging markets via licensing and local partnerships to convert export percentage into higher-margin sales.

• Scale manufacturing to meet global regulatory standards and increase capacity for biologics.
• Forge international licensing deals and strategic alliances to accelerate market access for late-stage assets.
• Invest in talent and digitalization to improve R&D productivity and supply-chain resilience.

Aurisco Pharmaceutical Co.,Ltd. (605116.SS) - Vision Statement

• Honesty: transparent disclosures, accurate reporting, and clear communication across all operations.
• Integrity: compliance with regulatory standards, ethical clinical practices, and responsible supply‑chain management.
• One team, One dream: cross‑functional collaboration aligning R&D, manufacturing, commercial, and corporate teams toward common strategic goals.

• Governance and transparency: values drive internal controls, audit readiness, and stakeholder reporting cadence.
• Employee alignment: values-based leadership programs and cross‑department KPIs to maintain cohesion.
• Stakeholder trust: values inform contract ethics, supplier selection, and patient‑safety commitments.

• Ethics & compliance: periodic audits, mandatory staff training, and whistleblower mechanisms tied to KPIs.
• Collaborative metrics: cross‑functional project milestones, shared incentives, and retention targets to sustain "One team, One dream."
• Transparency measures: scheduled investor briefings, timely disclosure of material events, and adherence to reporting standards.